Immunotech Laboratories, Inc. Enters Into Negotiations With Uldic Investment Pvt. Ltd. For Market Development

Immunotech Laboratories, Inc. (OTCMARKETS: IMMB) Immunotech Laboratories, Inc.(the “Company”) and Immunotech Laboratories, BG (IMMB-BG”) the Company announced today that they have entered into negotiations with Uldic Investment Pvt. Ltd. (“Uldic” or the “Representative/Distributor”), located in Zimbabwe, to pursue the development of market opportunities and Clinical Testing for the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) in Africa, initially focusing on clinical testing for Hepatitis C in Mauritius Island and Malawi.

About Immunotech Laboratories, Inc.

Headquartered in Monrovia, CA, Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. The Company strives to become a leader in immuno-therapeutic treatment and prevention of HIV/AIDS, Cancer and other immuno related disorders.

For more information visit: http://www.immunotechlab.com Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Contact:

Immunotech Laboratories, Inc,

818-409-8988

[e-mail]

GIC

813-213-8156

Houston, Texas

Immunotech Laboratories, Inc,[e-mail]813-213-8156Houston, Texas